Concord Biotech Second Quarter 2025 Earnings: Beats Expectations

Concord Biotech (NSE:CONCORDBIO) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₹3.20b (up 22% from 2Q 2024).
• Net income: ₹957.4m (up 18% from 2Q 2024).
• Profit margin: 30% (down from 31% in 2Q 2024). The decrease in margin was driven by higher expenses.
• EPS: ₹9.15 (up from ₹7.74 in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Concord Biotech Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 8.3%. Earnings per share (EPS) also surpassed analyst estimates by 24%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 2.8% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Concord Biotech's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.